Figure 5.

mTOR activity is not necessary for its perinuclear localization in an established infection. (A) Immunofluorescence analysis of mock- or HCMV-infected HFs at 24 or 48 hpi. Where applicable, HCMV-infected cells were treated with the mTOR kinase inhibitor Torin1 from 2 to 48 hpi (Torin 2-48hpi) or from 24 to 48 hpi (Torin 24-48hpi). (Red) pp28; (green) mTOR; (blue) nuclei. (B) Western analysis of phosphor S6K (P-S6K), total S6K (T-S6K), and total 4E-BP1 (T-4E-BP1) shows the effectiveness of Torin1 inhibition of mTORC1. Note also the expected decrease in pp28 detected in HCMV-infected cells treated with Torin1 from 2 to 48 and 24 to 48 hpi compared with untreated cells at 48 hpi.